drugset / Trial / NCT03495609
Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers
Phase 4
Completed
33 enrolled
University Hospital, Ghent
Fox Chase Cancer Center · collabZiekenhuis Oost-Limburg · collab
NaSingle-groupOpen-labelPrevention
Summary
Specific aim: To establish the proof of principle that treatment of "high breast cancer risk" women with recombinant human chorionic gonadotropin (r-hCG) will change their breast epithelium's high risk genomic profile to one similar to that identified in women with a history of early full first term pregnancy.
Timeline
- Start
- 2016-02-17
- Primary completion
- 2018-12-18
- Completion
- 2018-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ovidrel | Protein / enzyme biologic | 250 ug | Other |